Skip to main content

Table 2 Comparisons between patients with or without anemia

From: Prevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report

 

1 year post-transplant

5 years post-transplant

Anemic

Non-anemic

P value

Anemic

Non-anemic

P value

 

(n = 15)

(n = 125)

(n = 23)

(n = 95)

Age (years)

38 ± 11.8

38.9 ± 10.3

0.744

40.3 ± 9.1

42.3 ± 10.2

0.385

Gender (male/female)

10/5

88/37

0.766

16/7

69/26

0.769

BUN (mmol/L)

10.8 ± 6.1

6.9 ± 2.0

0.001

13.5 ± 8.1

7.1 ± 2.2

<0.001

Creatinine (mg/dL)

1.8 ± 0.6

1.3 ± 0.3

0.001

2.0 ± 0.8

1.3 ± 0.2

<0.001

Ccr

Mean

51.1 ± 20.8

69.1 ± 17.3

<0.001

48.1 ± 21.9

65.8 ± 13.7

<0.001

>75 mL/min/1.73 m2

2 (13.3%)

40 (32%)

0.136

4 (17.4%)

25 (26.3%)

0.372

50 to 75 mL/min/1.73 m2

4 (26.7%)

70 (56%)

0.032

4 (17.4%)

61 (64.2%)

<0.001

<50 mL/min/1.73 m2

9 (60%)

15 (12%)

<0.001

15 (65.2%)

9 (9.5%)

<0.001

Immunosuppression

Tac/CsA

3/12

30/95

0.73

3/20

28/67

0.108

MMF/AZT

12/3

110/15

0.382

21/2

81/14

0.448

ACEI or ARB (yes/no)

1/14

19/106

0.372

5/18

16/79

0.58

Iron medicine (yes/no)

11/4

12/113

<0.001

17/6

6/89

<0.001

  1. ARB, angiotensin receptor blockers; ACEI, angiotensin-converting-enzyme inhibitors; AZT, azathioprine; BUN, blood urea nitrogen; Ccr, calculated creatinine clearance; CsA, cyclosporin A; MMF, mycophenolate mofetil; Tac, tacrolimus.